Saccharomyces boulardii's Impact on Pediatric Diarrhea-Predominant Irritable Bowel Syndrome: Animal Model Findings

1. This study investigated the efficacy and mechanism of Saccharomyces boulardii in the treatment of children with diarrheal irritable bowel syndrome (IBS-D) through clinical trials and animal models. 2. The specific role of Saccharomyces boulardii in the treatment of IBS-D is described, supplementing the evidence in the existing literature. Through animal experiments and microbial analysis, its role in regulating intestinal microbiota and immune response was further elucidated. 3. The results suggest that Saccharomyces boulardii can treat IBS-D in children, providing clinicians with new treatment options and stimulating more research into the role of probiotics in regulating gut health and immune response.